M. Casadebaig

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

M. Czuczman, A. Santoro, K. Izutsu, 2022, Cancer Reports.

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

R. Greil, P. Gaulard, B. Coiffier, 2019, British journal of haematology.

Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

R. Greil, U. Jäger, L. Trümper, 2021, International Journal of Hematology.

Estimands for overall survival in clinical trials with treatment switching in oncology

K. Rufibach, Y. Shentu, J. Dey, 2021, Pharmaceutical statistics.

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

S. Usmani, N. Shah, A. Truppel-Hartmann, 2020 .

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.

R. Greil, U. Jäger, L. Trümper, 2019, Journal of Clinical Oncology.

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

M. Czuczman, R. Bouabdallah, J. Radford, 2019, Blood.